NCT03705065View on ClinicalTrials.gov

Bupivacaine HCl PK and Safety in Augmentation Mammoplasty

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 19, 2018

Primary Completion Date

October 8, 2018

Study Completion Date

November 5, 2018

Conditions
Analgesia
Interventions
DRUG

Bupivacaine HCl

Bupivacaine HCl without epinephrine 0.25%, 60 mL (30 mL per pectoral pocket)

Trial Locations (1)

77027

Hermann Drive Surgical Hospital, Houston

Sponsors

Lead Sponsor

Heron Therapeutics
All Listed Sponsors
lead

Heron Therapeutics

INDUSTRY